| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2004;26:173-182
© 2004 Elsevier Science NL
Cancer Division, Medical Research Council Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Received 22 October 2003; received in revised form 10 March 2004; accepted 18 March 2004.
* Corresponding author. Tel.: +44-207-670-4737
e-mail: rs{at}ctu.mrc.ac.uk
Objectives: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival benefit for cisplatin-based chemotherapy when given in addition to surgery, radical radiotherapy or ‘best supportive care’. However, it included many small trials and trials with differing eligibility criteria and chemotherapy regimens. The aim of the Big Lung Trial was therefore to run a large pragmatic trial to confirm the survival benefits seen in the meta-analysis. Methods: In the surgery setting, a total of 381 patients were randomised to chemotherapy (C, 192 patients) or no chemotherapy (NoC, 189 patients). C was three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin. Results: Chemotherapy was given before surgery in 3% of patients whilst 97% received adjuvant chemotherapy. Baseline characteristics were: median age 61 years, 69% male, 48% squamous cell, 93% WHO PS 0-1, 27% stage I, 38% stage II, and 34% stage III. Complete resection was achieved in approximately 95% of patients. In the C group, 13% received no chemotherapy, 21% one or two cycles, and 64% all three cycles of their prescribed chemotherapy (60% of the latter with no delays or modification). 30% had grade 3/4 toxicity, mainly haematological, nausea/vomiting and neutropenic fever, and six patients were reported as having a treatment-related death. 198 (52%) of patients have died, but there is currently no evidence of a benefit in overall survival to the C group: HR 1.02 (95% CI 0.77–1.35), P=0.90). Conclusions: This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I–III NSCLC. However, the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival benefit with cisplatin-based chemotherapy.
Key Words: Non-small cell lung cancer • Surgery • Chemotherapy
This article has been cited by other articles:
|
|
 |
|
  A. J. Wozniak and S. M. Gadgeel Review: Adjuvant therapy for resected non-small cell lung cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 109 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population Ann. Onc., August 28, 2009; (2009) mdp360v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schettino, M. A. Bareschino, A. Rossi, P. Maione, V. Castaldo, N. Mazzeo, P. C. Sacco, M. L. Ferrara, G. Palazzolo, F. Ciardiello, et al. Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 5 - 13. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Miksad, M. Gonen, T. J. Lynch, and T. G. Roberts Jr Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2245 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chhatwani, E. Cabebe, and H. A. Wakelee Adjuvant Treatment of Resected Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shukuya, T. Takahashi, A. Tamiya, A. Ono, S. Igawa, A. Tsuya, Y. Nakamura, H. Murakami, T. Naito, K. Kaira, et al. Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study Jpn. J. Clin. Oncol., March 1, 2009; 39(3): 158 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bordoni Consensus Conference: Multimodality Management of Early- and Intermediate-Stage Non-Small Cell Lung Cancer Oncologist, September 1, 2008; 13(9): 945 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fruh, E. Rolland, J.-P. Pignon, L. Seymour, K. Ding, H. Tribodet, T. Winton, T. Le Chevalier, G. V. Scagliotti, J. Y. Douillard, et al. Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3573 - 3581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Pignon, H. Tribodet, G. V. Scagliotti, J.-Y. Douillard, F. A. Shepherd, R. J. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group J. Clin. Oncol., July 20, 2008; 26(21): 3552 - 3559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ost, J. Goldberg, L. Rolnitzky, and W. N. Rom Survival after Surgery in Stage IA and IB Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 516 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M.W. Pisters, W. K. Evans, C. G. Azzoli, M. G. Kris, C. A. Smith, C. E. Desch, M. R. Somerfield, M. C. Brouwers, G. Darling, P. M. Ellis, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline J. Clin. Oncol., December 1, 2007; 25(34): 5506 - 5518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ng, B. Hasan, N. Mittmann, M. Florescu, F. A. Shepherd, K. Ding, C. A. Butts, Y. Cormier, G. Darling, G. D. Goss, et al. Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., June 1, 2007; 25(16): 2256 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild Lung Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dubey and C. A. Powell Update in Lung Cancer 2006 Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 868 - 874. [Full Text] [PDF]
|
|
|
|
|
|
H. Wakelee, S. Dubey, and D. Gandara Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer--How to Handle Stage I Disease Oncologist, March 1, 2007; 12(3): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later. Thorax, December 1, 2006; 61(12): 1023 - 1028. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Molina, A. A. Adjei, and J. R. Jett Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest, October 1, 2006; 130(4): 1211 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. West, A. J.B. Kirk, and J. Dunning Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 488 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Spiro and G. A. Silvestri One Hundred Years of Lung Cancer Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 523 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dunant, J.-P. Pignon, and Thierry Le Chevalier on behalf of the Internationa Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: Contribution of the International Adjuvant Lung Trial Clin. Cancer Res., July 1, 2005; 11(13): 5017s - 5021s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson and M. S. Rabin Patient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5022s - 5026s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Thatcher, C. Faivre-Finn, F. Blackhall, H. Anderson, and P. Lorigan Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5051s - 5056s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
